bullish
Taisho Pharma Seems the Best Suitor for Takeda’s Japan OTC Business
434 Views24 Jun 2020 13:40
It was reported by several news media outlets that Blackstone, Bain Capital, CVC Capital Partners and Taisho Pharmaceutical are among the final...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 6-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Shin-Etsu: All Segments Seeing Declines; Earnings Rebound Could Take Longer31 Jul 2020
- Hoya 1Q Results: Another Quarter Impacted by the Pandemic but Recovery Is Ahead29 Jul 2020
- Olympus Finally Sells Its Loss-Making Camera Business25 Jun 2020
- Hygeia Healthcare IPO (Part I): A Better Healthcare16 Jun 2020
- Takeda Offloads Asia-Focused Drugs to South Korea’s Celltrion12 Jun 2020
- Takeda Pharma Divests Yet Another Non-Core Asset to Pay-Off Debt and Focus on Core Areas29 Apr 2020
x